Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Work ongoing on election-delayed DAMA:

This article was originally published in Clinica

Executive Summary

The German competent authority, BfArM, which oversees pharmaceutical product registration and materio- and pharmacovigilance, has been restructured in what is seen as the first phase of changes ahead of its eventual transformation into an agency, called DAMA. The new German pharmaceutical and medical products agency, whose passage into law has, however, been delayed by the SPD's early election call, will have a high level of autonomy and a modern management structure with which to set policy for the E23bn pharmaceutical and E20bn medical technology sectors, said temporary institute head Professor Reinhard Kurth. A law enacting DAMA will have to await the next legislative period.

You may also be interested in...



Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.

Topics

UsernamePublicRestriction

Register

MT055941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel